



CLX Medical, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

April 2008 Newsletter

CLX Investment Company Announces Implementation of New Corporate Name - CLX Medical, Inc.

Company Will Immediately Begin Branding Efforts to Reflect Focus on Multiple Products in the Medical Diagnostic Testing Market

C LX Investment Company, Inc., which is focused on the launch and distribution of unique medical diagnostic testing products, announced on April 21, 2008 that the company began operating under its new corporate name, CLX Medical, Inc.

The change was initiated to more accurately reflect CLX's current focus and expected future as a leader in the launch of medical diagnostic testing products. CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets.

In addition to Zonda's chlamydia product, CLX recently announced that the company has identified a rapid diagnostic device for the medical market that it has targeted for potential acquisition (see page 3 of this newsletter). As additional due diligence and negotiations are undertaken, the company expects to enter into an initial agreement in the form of a letter of intent for the acquisition of the device.

CLX has stated as its core focus to seek additional products and technologies for the company to become involved with as they are presented.

A Schedule 14C Information Statement was filed with the Securities and Exchange Commission on April 9, 2008 reporting majority shareholder approval on the proposal to change the company's name.

According to information the company has received since filing the information statement, the company's CUSIP number will remain the same, and the Board believes that CLX's stock trading symbol will also remain the same.

"As we prepare to begin the clinical trials for the Zonda chlamydia product and move forward with the acquisition of another rapid diagnostic testing device, changing the company's name to CLX Medical, Inc. will help to identify CLX within the medical supply industry," stated Vera Leonard, chief executive officer of Zonda and CLX. "Shareholders should now look for additional information related to the operations of CLX, including our acquisition candidate and the validation study for Zonda's chlamydia test."

Inside This Issue

Greeting from CEO Vera Leonard
Page 2

Master distributor targeted for medical diagnostics testing products in European markets
Page 2

New targeted medical diagnostic product acquisition announced
Page 3

Laboratory is selected for validation study on Zonda's chlamydia test
Page 3

About the Company

CLX Medical, Inc. is focused on the launch and distribution of unique medical diagnostic testing products. CLX holds a 51% equity interest in Zonda, Inc. and holds a common stock position, in ActionView International, Inc., a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

For more information, please visit the CLX website at www.clxinvestments.com and the Zonda website at www.zondaincusa.com.

CLX Medical, Inc. Targets Master Distributor for Its Medical Diagnostic Testing Products in the European Market

CLX Medical, Inc. has identified and is in negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market.

The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.

"A highly capable and established master distributor for the European market will provide a number of significant advantages for CLX as we pursue widespread distribution for our subsidiary products and additional medical diagnostic tests that we may choose to acquire or license," stated Vera Leonard, chief executive officer of Zonda and CLX.

"We are pleased to have identified just such a company, which we believe will serve as a true partner as we seek to expand distribution of our products in the European market.

"We expect to successfully complete negotiations and enter into an agreement with the prospective master distributor. Key terms of the relationship have been agreed upon and we are moving forward with definitive negotiations," added Ms. Leonard.

CLX currently holds a majority interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests, including a rapid point of care test for chlamydia. Zonda's chlamydia product has been distributed in Europe for approximately three years.

CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets.

As part of the preparation for clinical trials, a validation study has been commissioned in order to perfect the testing protocol.

Greetings from the CEO

I am pleased to present to CLX shareholders this month's edition of our corporate newsletter.



Since we issued our last newsletter, CLX has completed a number of very positive steps toward its goal of becoming a leader in the distribution of rapid medical diagnostic testing products.

While it may appear to be somewhat a cosmetic change, the adoption of a new name, CLX Medical, Inc., is significant in the development of the company. It has helped to identify CLX in the appropriate industry, both for our public company audience and within the medical supply industry. We will continue our branding efforts so that as we achieve milestones under the CLX Medical name, it will be easier to leverage that success into additional deal flow and a greater degree of attention in the financial markets.

We continue to prepare for clinical trials for Zonda's chlamydia test with the beginning of validation study that will perfect the testing protocol. As we have stated in our recent press releases, the results from the validation study may be helpful for us to pursue a relationship with an established company in the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process. The results may also assist us in overseas markets where additional clinical data can support the sales of the products currently in the market.

Virtually all of the areas in which we have stated a specific focus for CLX have been positively moved forward over the last several weeks. We expect this progress to continue.

Management understands that the current trading price of CLX stock seems out of balance with the expected outcomes for the company, and we want shareholders to know that we are working as hard as possible to ensure that the value of the company begins to be reflected in our stock price.

Best regards,

Vera Leonard,
Chief Executive Officer

Results from the validation study may be helpful in other applications, such as in overseas markets where additional clinical data can support the sales of the products currently in the market. CLX may also pursue a strategic alliance relationship with an established company in the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process, and the validation study may help to secure such a relationship.

Forward-Looking Statements

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

CLX Announces New Targeted Acquisition in the Medical Diagnostic Testing Market

Rapid Diagnostic Device Has Already Achieved Necessary Clearance for Distribution in the U.S. Market

A new targeted acquisition in the medical diagnostics testing market has been identified by CLX Investment Company, which recently changed its name to CLX Medical, Inc.

As additional due diligence and negotiations are undertaken, the company expects to pursue an initial agreement in the form of a letter of intent for the acquisition of the device.

CLX is currently preparing to initiate clinical trials for Zonda's rapid point of care test for chlamydia as part of the effort to achieve FDA clearance for the product. The company recently announced an upcoming validation study to perfect the testing protocol in preparation for the clinical trials.

As CLX supports the Zonda product line, it will continue to identify additional innovative products as potential acquisitions and opportunities for distribution relationships for CLX. CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States.

"Identifying additional potential acquisitions falls in line with CLX's stated goal to establish itself with multiple products in the medical diagnostic testing market, and having a product with all of the necessary clearances for sale in the U.S. would also allow us to begin utilizing our existing relationships with major domestic distributors," commented Vera Leonard, chief executive officer of Zonda and CLX.


"The relationships we have established over the past several months, including with American Health Partners and its sub-contractor, Safis Solutions, brings additional credibility to our team and allows for greater capacity to bring on new acquisitions.

"The fact that the targeted acquisition is a rapid diagnostic test presents considerable synergies with our efforts on behalf of the Zonda product. We believe that this type of acquisition would allow CLX to immediately increase its profile in the medical supply market, particularly in the rapid diagnostic segment," Ms. Leonard added.

In addition to the U.S. market, the new acquisition may have significant potential in Europe, where the Zonda chlamydia product is sold, and other overseas markets.

Laboratory Selected To Conduct Pre-Clinical Trials Validation Study on Zonda's Rapid Point of Care Test for Chlamydia

CLX Medical, Inc announced that the company has selected IIT Research Institute (IITRI) (<http://www.iitri.org>) to serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia. A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.



IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. Its scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development.

Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world.



IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility. It holds accreditations, licensures and registrations a variety of organizations and agencies including the United States Department of Agriculture, the United States Drug Enforcement Agency, and the United States Centers for Disease Control.

"We are pleased to have selected the laboratory that will conduct the validation study for the Zonda chlamydia product and to have selected a lab with the experience and expertise of IITRI," commented CEO Vera Leonard. "The study is expected to provide information that will be useful beyond just the clinical trials, so its importance to the advancement of the Zonda product should not be understated."